Omalizumab reduces allergic rhinitis symptoms due to Japanese cedar pollen by improving eosinophilic inflammation
Rhinology Journal · 2024
DOI: 10.4193/rhin24.105 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rhinology Journal, 2024. Verfasst von K Hirano und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Showa University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Omalizumab, Rhinitis, Allergic, Seasonal, Pollen, Cryptomeria. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Seasonal allergic rhinitis caused by Japanese cedar pollen (SAR-JCP) is a serious social problem in Japan, affecting 38.8% of the population (1). Omalizumab, a recombinant humanised monoclonal anti-immunoglobulin (Ig)E antibody, reduces serum-free IgE levels by 84–99% (2). The reduction of serum-free IgE levels induced by omalizumab ultimately downregulates FcεRI expression in basophils and mast cells (3). Omalizumab significantly reduces nasal symptoms and improves the quality of life in patients with allergic rhinitis (4,5); however, other than a decrease in free IgE, its biomarker activity is unclear. Allergic rhinitis reactions are more pronounced in nasal secretions and mucosa than in serum; however, no studies have examined the changes in proteins in nasal secretions after omalizumab administration. In this study, we aimed to elucidate the pathophysiology of the effect of omalizumab. This may serve as a basis for the identification of new biomarkers through the examination of proinflammatory proteins in nasal secretions, which may reflect the pathophysiology more accurately than peripheral blood.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Showa University School of Medicine, Tokyo, Japan.
- Department of Hygiene, Public Health and Preventive Medicine, Showa University School of Medicine, Tokyo, Japan.
- Department of Radiology, Division of Radiation Oncology, Showa University School of Medicine, Tokyo, Japan.
- Division of Oral Functional Rehabilitation Medicine, Department of Oral Health Management, School of Dentistry, Showa University, Tokyo, Japan.
- Department of Internal Medicine, Division of Respiratory Medicine and Allergology, Showa University School of Medicine, Tokyo, Japan.
Zitieren
APA
Hirano, K., Suzaki, I., Okuzawa, N., Oki, A., Otani, Y., Takeuchi, M., Minoura, A., Murakami, K., Ihara, Y., Kato, H., Watanabe, Y., & Shimane, T. (2024). Omalizumab reduces allergic rhinitis symptoms due to Japanese cedar pollen by improving eosinophilic inflammation. Rhinology Journal. https://doi.org/10.4193/rhin24.105
Vancouver
Hirano K, Suzaki I, Okuzawa N, Oki A, Otani Y, Takeuchi M, et al. Omalizumab reduces allergic rhinitis symptoms due to Japanese cedar pollen by improving eosinophilic inflammation. Rhinology Journal. 2024. doi:10.4193/rhin24.105
BibTeX
@article{Hirano2024,
author = {Hirano, K and Suzaki, I and Okuzawa, N and Oki, A and Otani, Y and Takeuchi, M and Minoura, A and Murakami, K and Ihara, Y and Kato, H and Watanabe, Y and Shimane, T},
title = {Omalizumab reduces allergic rhinitis symptoms due to Japanese cedar pollen by improving eosinophilic inflammation},
journal = {Rhinology Journal},
year = {2024},
doi = {10.4193/rhin24.105}
}
EUVIMED